title: Original version Date: 18/05/2017
text: |
  Original version Date: 18/05/2017
  |
  bet | 548/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Original version Date: 18/05/2017
  |
  Author: NMF Consensus Group
  |
  Current Version number: 2.0
  |
  Current Version Date: 16/11/2020
  |
  Risk Rating:
  |
  Due for Review: 16/11/2025
  |
  Approval by: DTC
  |
  Approval Date: TBA
  |
  Sildenafil |
  Revision Date : 23-12-2020
  |
  Approved: TC/KOH
  |
  Alert
  |
  Data in neonates are limited. Use in neonates should be restricted and considered experimental. Further studies are needed.
  |
  Indication
  |
  Persistent Pulmonary Hypertension of the Neonate (PPHN):
  - refractory to inhaled nitric oxide (iNO) and other conventional therapies or
  - those who are persistently unable to be weaned off inhaled nitric oxide or
  - in situations where inhaled nitric oxide and high frequency ventilation are not available
  Chronic pulmonary hypertension secondary to respiratory, cardiac or chest wall disease.
  |
  Action
  |
  Selective phosphodiesterase type 5 (PDE5) inhibitor. PDE5 is found in the smooth muscle of the pulmonary vasculature, where it is responsible for the degradation of cyclic guanosine monophosphate (cGMP). cGMP produces smooth muscle relaxation. Sildenafil increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary hypertension, this can lead to selective vasodilatation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation.
  |
  Drug Type
  |
  Phosphodiesterase type 5 (PDE5) inhibitor.
  |
  Trade Name
  |
  IV: Revatio
  Oral: Pharmacy prepared
  |
  Presentation
  |
  IV: Vial for injection containing 10 mg/12.5 mL = 0.8 mg/mL of sildenafil
  Oral: Pharmacy-prepared oral suspension
  |
  |
  |
  | |